Nuvalent reports Q3 net loss $84.3M; cash $1.2B; pipeline on track for 2025 pivotal data

Nuvalent, Inc.

2024-Q3 EPS reported -$2.87

Net loss $84.3M for Q3 2024; R&D expenses $60.6M, G&A $15.8M.
Cash, cash equivalents and marketable securities $1.2B, expected to fund operations into 2028.
Zidesamtinib (ROS1+) Phase 1 data at ESMO; Phase 2 enrollment ongoing (227 patients), pivotal data expected 2025.
NVL-655 (ALK+) Phase 2 enrollment ongoing (229 patients); ALKAZAR Phase 3 trial to start H1 2025.
Appointed Dr. Alice Shaw to Scientific Advisory Board; upsized public offering raised $575M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.